POMALYST (pomalidomide)

SELF ADMINISTRATION - ORAL

Indications for Prior Authorization:

  • Treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy

Patients must meet the following criteria for the indication(s) above:

  • Chart note documentation from the following specialist is provided confirming diagnosis, AND
  • Patient is 18 years of age or older, AND
  • Patients must have received two prior therapies including lenalidomide (Revlimid®) and bortezomib (Velcade®) and have had disease progression within 60 days of completion of the last therapy

The Following Conditions Do Not Meet the Criteria for Use as Established by the WHA P & T Committee:

  • All non-FDA approved uses not listed in the approved indications
  • Patient must be pregnant or attempting to become pregnant

Recommended Dosing:

  • The recommended dose is 4 mg once daily on days one to 21 of a repeated 28 day cycle
  • Pomalyst should be given in combination with dexamethasone

Box warnings:

  • Embryo-fetal toxicity, venous thrombosis

Approval:

One year


 

Last review date: January 3, 2020

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone